W. R. Bell, M.D.
This content is PDF only. Please click on the PDF icon to access.
A coagulating proteolytic enzyme that removes fibrinogen from the blood is now being used experimentally to treat patients with various types of thrombotic disease. The agent, Arvin, is obtained by column chromatographic fractionation of the crude venom of the Malayan pit viper, Agkistrodon rhodostoma. Effectiveness of intravenous administration is being evaluated in a variety of thrombotic disorders. With this route there has been no evidence of resistance to therapy, dose response variation, or tachyphylaxis. Control of therapy is guided by the measurement of plasma fibrinogen concentration, which is maintained below 20 mg/100 ml. Levels of other clotting factors, platelets, and
Bell WR. Treatment of Thromboembolic Disease by Defibrinogenation with Arvin.. Ann Intern Med. ;74:825–826. doi: 10.7326/0003-4819-74-5-825_4
Download citation file:
Published: Ann Intern Med. 1971;74(5):825-826.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use